CCL2 and rheumatoid arthritis: In this regard, the data from 2 randomized, controlled RA clinical trials were re-examined in which experimental therapies designed to neutralize either monocyte chemotactic protein-1 (MCP-1) activity or the interaction between C5a and its receptor C5aR were assessed with each of these strategies failing to show clinical efficacy.